Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
36 results
D1.257 - Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies
D1.259 - Icatibant Use During Pregnancy: A South African Case Series
D1.261 - Phenotypic and Immunological Profiles of Chronic Urticaria: A Cross- Sectional Study From South India
D1.250 - Real-World Effectiveness and Safety of Icatibant for Hereditary Angioedema in China: An Interim Analysis of the EASTERN Study
D1.251 - High Cost of Stigma: Anticipated Workplace Stigma Drives Absenteeism while Healthcare Stigma Provokes Anxiety in HAE
D1.253 - Probiotic Co-administration to Improve Gastrointestinal Tolerability of Berotralstat in Hereditary Angioedema: a multicenter case series from the ITACA network
D1.254 - Comparison Between Classical and Updated Classifications in Patients Diagnosed with Isolated Angioedema: Finally, Did We Find the Ideal One?
D1.255 - Is it Angioedema? Unmasking a complete Melkersson-Rosenthal Syndrome
D1.256 - Chronic Inducible Urticaria in Real Life: A Single-Centre Retrospective Cohort
D1.258 - First real-life experiences with Sebetralstat as oral on-demand treatment for acute HAE attacks documented in a global angioedema disease registry
D1.260 - Clinical Characteristics and Hospitalization Patterns in Chronic Spontaneous Urticaria Patients in Bulgaria
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download